Jeremy Grantham Ngm Biopharmaceuticals Inc Transaction History

Grantham, Mayo, Van Otterloo & Co. LLC

  • $29.2 Billion
  • Q2 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 14, 2023
SELL
$2.44 - $4.53 $29,043 - $53,920
-11,903 Reduced 45.26%
14,397 $37,000
Q1 2023

May 12, 2023
BUY
$3.72 - $5.4 $97,836 - $142,020
26,300 New
26,300 $107,000

Others Institutions Holding NGM

# of Institutions
5
Shares Held
2.6M
Call Options Held
300
Put Options Held
0
View Full List

About NGM BIOPHARMACEUTICALS INC

NGM Quotes by TradingView
  • Ticker NGM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 80,365,904
  • Description
  • NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trial...
More about NGM
Track Jeremy Grantham's Portfolio

Track Jeremy Grantham Portfolio

Follow Jeremy Grantham (Grantham, Mayo, Van Otterloo & Co. LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Grantham, Mayo, Van Otterloo & Co. LLC, based on Form 13F filings with the SEC.

News

Stay updated on Grantham, Mayo, Van Otterloo & Co. LLC and Jeremy Grantham with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email